Search research articles
Contact Us
Filters
Showing results (251-260 of 286) with videos related to
Page
of 29
Sort By:
Plos Medicine
|
December 16, 2021
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial
Fred C Semitala, Jillian L Kadota, Allan Musinguzi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Trials
|
November 28, 2017
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
Tara C Bouton, Patrick P J Phillips, Carole D Mitnick, et al.
Antimicrobial Agents and Chemotherapy
|
July 18, 2018
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Charles A Peloquin, Patrick P J Phillips, Carole D Mitnick, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
International Journal of Geriatric Psychiatry
|
October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)
Martin Knapp, Derek King, Renée Romeo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
The Lancet. Neurology
|
October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses
Robert Howard, Rupert McShane, James Lindesay, et al.
The New England Journal of Medicine
|
April 29, 2026
Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples
Seda Yerlikaya, Masuzyo Chirwa, Bukola Ajide, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 286) with videos related to
Sort By:
Page
of 29
Plos Medicine
|
December 16, 2021
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial
Fred C Semitala, Jillian L Kadota, Allan Musinguzi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
Elin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Trials
|
November 28, 2017
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
Tara C Bouton, Patrick P J Phillips, Carole D Mitnick, et al.
Antimicrobial Agents and Chemotherapy
|
July 18, 2018
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Charles A Peloquin, Patrick P J Phillips, Carole D Mitnick, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
International Journal of Geriatric Psychiatry
|
October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)
Martin Knapp, Derek King, Renée Romeo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
The Lancet. Neurology
|
October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses
Robert Howard, Rupert McShane, James Lindesay, et al.
The New England Journal of Medicine
|
April 29, 2026
Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples
Seda Yerlikaya, Masuzyo Chirwa, Bukola Ajide, et al.
Page
of 29